Floatz logo

Glatiramer

Thyroid Cancer

Institut du Cancer de Montpellier - Val d'Aurelleprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

49 Active assets in the Thyroid Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Kineta Inc.
Phase 2BB
Cyclophosphamide
Anusha Kalbasi
Phase 2B
Epirubicin
Salubris Biotherapeutics Inc
Phase 2B
Denosumab
Amgen
Phase 2B
[68ga]ga-nota-t4
RenJi Hospital
Phase 2/3CCC

View all 50 →

Same molecule, other indications

Glatiramer is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
67 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →